Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -48.19% | -319.27% | 78.60% | -58.16% | -298.57% |
| Total Depreciation and Amortization | 6.92% | -22.44% | -0.97% | -58.10% | 87.12% |
| Total Amortization of Deferred Charges | 0.97% | 0.15% | -0.15% | 48.67% | 2,947.46% |
| Total Other Non-Cash Items | 48.13% | 32.87% | -23.95% | -18.46% | 146.51% |
| Change in Net Operating Assets | 209.35% | 42.21% | -308.25% | -86.18% | 23.45% |
| Cash from Operations | 45.38% | -69.57% | 32.53% | -110.12% | -110.57% |
| Capital Expenditure | 81.25% | -128.57% | -20.69% | -81.25% | 89.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 81.25% | -128.57% | -20.69% | -81.25% | 89.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 37.50% | -60.00% | 0.00% | 99.99% | -779,520.00% |
| Issuance of Common Stock | -12.95% | -88.79% | -97.92% | 2,187.90% | -27.53% |
| Repurchase of Common Stock | 99.50% | -3,940.00% | 99.44% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,023.53% | -100.99% | -97.91% | 1,988.96% | -21.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.01% | -124.71% | -107.47% | 6,925.65% | -142.12% |